Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous advanced NSCLC (Stage IV).~* Participants must have progressed on one prior line of platinum-based chemotherapy in the advanced or metastatic setting.~* Measurable disease as measured by response evaluation criteria in solid tumors (RECIST) criteria v 1.1.~* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.~* Able to swallow the study drugs whole.~* Adequate organ function.~* Women of childbearing potential must have a negative serum or urine pregnancy test performed ≤ 7 days prior to start of treatment. Women of childbearing potential or men with partners of childbearing potential must use effective birth control measures during treatment and during the 3 months following completion of study treatment.~Exclusion Criteria:~* Participants who have received \> 1 prior line of chemotherapy in the advanced or metastatic setting. (Immunotherapy will not be considered a line of chemotherapy.)~* Prior treatment with a PI3K/mTOR inhibitor, epidermal growth factor receptor (EGFR) inhibitor, and/or necitumumab.~* History of brain metastases unless irradiated ≥ 2 weeks prior to first study treatment and stable without requirement of corticosteroids.~* Have serious pre-existing medical conditions.~* Have insulin-dependent diabetes mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate control of blood glucose level is obtained by oral anti-diabetics.~* Women who are pregnant or breast-feeding.~* Clinically significant electrolyte imbalance ≥ Grade 2.~* Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin and oral Xa inhibitors are allowed.~* Have initiated treatment with bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents (e.g. denosumab) ≤ 28 days prior to Day 1 of Cycle 1.~* Concurrent serious infection requiring parenteral antibiotic therapy.~* Have a second primary malignancy that in the judgment of the investigator and Medical Monitor may affect the interpretation of results.~* Have an active, known fungal, bacterial, and/or known viral infection.~* History of arterial or venous embolism within 3 months prior to study enrollment. If the embolism occurred \>3 and \<6 months, the participant is eligible provided appropriate treatment according to institutional standard of care is ensured.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3023414 + Necitumumab (Type: EXPERIMENTAL): 200 milligrams (mg) LY3023414 administered orally twice daily and 800 mg necitumumab administered intravenously (IV) on day 1 and day 8 of each cycle (21 day cycles). Participants may continue to receive treatment until discontinuation criteria are met.

Based on this trial design, predict the completion outcome and termination type (if applicable).